Level D· Scientific groundwork from lab and animal studiesLaboratory StudyPubMed

Paclitaxel Priming of TRAIL Expressing Mesenchymal Stromal Cells (MSCs- TRAIL) Increases Antitumor Efficacy of Their Secretome.

Coccè V., Bonomi A., Cavicchini L., Sisto F., Giannì A., Farronato G.

Laboratory Study on Systemic / IV, published in Curr Cancer Drug Targets (2021) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
Curr Cancer Drug Targets (2021)
Country
Netherlands
Reported sample size
—
Source database
PubMed
PMID
33200709
DOI
10.2174/1568009620666201116112153

Abstract (original English)

Adipose tissue-derived MSCs engineered with the tumor necrosis factor- related apoptosis-inducing ligand protein (MSCs-TRAIL) have significant anticancer activity. MSCs, without any genetic modifications, exposed to high doses of chemotherapeutic agents are able to uptake the drug and release it in an amount affecting tumor proliferation. The purpose of this study was to verify the ability of MSCs-TRAIL to uptake and release paclitaxel (PTX) by providing an increased antitumor efficacy. MSCs and MSCs-TRAIL were tested for their sensitivity to Paclitaxel (PTX) by MTT assay, and the cells were loaded with PTX according to a standardized procedure. The secretome was analysed by HPLC for the presence of PTX, microarray assay for soluble TRAIL (s-TRAIL) and tested for in vitro anticancer activity. MSCs-TRAIL were resistant to PTX and able to incorporate and then release the drug. The secretion of s-TRAIL by PTX loaded MSCs-TRAIL was not inhibited, and the PTX delivery together with s-TRAIL secretion resulted in increased antitumor efficacy of cell secretome as tested in vitro on human pancreatic carcinoma (CFPAC-1) and glioblastoma (U87-MG). Our result is the first demonstration of the possible merging of two new MSCs therapy approaches based on genetic manipulation and drug delivery. If confirmed in vivo, this could potentiate the efficacy of MSCs-TRAIL and strongly contribute to r

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
PaclitaxelMesenchymal Stem CellsHumansTNF-Related Apoptosis-Inducing LigandAntineoplastic Agents, PhytogenicSecretomeCell Line, TumorPancreatic NeoplasmsGlioblastoma

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research